Severe and disabling joint pain has been connected to the use of dipeptidyl peptidase-4 inhibitors and combination therapies for diabetes, prompting a new FDA warning…
Search results for: hip
Methotrexate Halt Feasible in Some Etanercept RA Responders
NEW YORK (Reuters Health)—Certain rheumatoid arthritis (RA) patients doing well on etanercept and methotrexate may be able to quit the latter agent if they have tolerability problems, according to an open-label Canadian study. In a Sept. 11 online paper in Rheumatology, Dr. Boulos Haraoui, of the University of Montreal, and colleagues noted that although combination…
New Labeling for Infused Golimumab; Phase 3 Trial for Romosozumab Promising
The FDA has approved new labeling for infused golimumab to include measures of mental and physical health. Plus romosozumab meets primary endpoints in postmenopausal women with osteoporosis during a Phase 3 trial…
Connective Tissue Disorders Lack Societal Concern, Financial Support
“Love is the bone and sinew of my curse.” —Sylvia Plath Cutting the Cord Here’s the problem: No one grows up wanting to seek the cure for bursitis—or tendonitis or just about any of the other seemingly mundane maladies afflicting our body’s scaffolding. Meniscal tears, fasciitis, tendinopathies—the list is endless. Chances are, your college essay…
Rheumatologists on the Move, September 2015
Teresa Fama: Rheumatologist to Chair Public Advisory Council Teresa Fama, MD, is the new chair of the New England Comparative Effectiveness Public Advisory Council (CEPAC). A rheumatologist who practices in Berlin, Vt., Dr. Fama has previous experience in public policy, specifically health policy. Before she began her second career as a physician, Dr. Fama was…
Vitamin D in Rheumatology: Cause and Effect Unclear
The controversy over vitamin D is hearty enough to confuse even seasoned rheumatologists, says Nathan Wei, MD, The Arthritis Treatment Center, Frederick, Md. “It’s like what you hear with coffee. One week, [a study finds] coffee is … good for you; the next week, there’s a study saying it’s bad for you,” he says. Vitamin…
Preparing Immunocompromised Patients for Risks of Traveling Abroad
Summer is a season for travel, so if your immunocompromised patients plan to journey to regions where there are outbreaks of infections, such as chikungunya, tuberculosis, typhoid, yellow fever or other diseases, communication and preparation may prevent serious health events. “The world teems with disease-causing organisms, and almost every infection is more serious in the…
Fellow’s Forum Case Report: Limited Cutaneous Systemic Sclerosis
Systemic sclerosis (SSc) is an acquired, sporadic, autoimmune, connective tissue disease with two subsets: limited cutaneous scleroderma (lcSSc) and diffuse cutaneous scleroderma (dcSSc). In the U.S., the annual incidence is about 20 cases per 1 million adults, with a prevalence of about 240 cases per 1 million adults.1 As with other connective tissue disorders, SSc…
Engaging Patients to Enhance Rheumatology Research
It takes a great deal of time and money to produce clinical practice guidelines for rheumatic diseases. No matter how well a treatment inhibits inflammatory cytokines, it won’t lower disease activity without one essential factor: patient compliance. “You can’t propose a treatment algorithm in your research that no patient would actually use,” says Veena Ranganath,…
Risk of Hearing Loss in Patients with Osteoporosis
People diagnosed with osteoporosis have almost twice the risk of developing hearing loss as those without the bone-fragile skeletal disease, according to results from a large retrospective study in Taiwan. The study looked at the risk of sudden sensorineural hearing loss (SSHL) using data collected from Taiwan’s National Health Insurance claims and is believed to…
- « Previous Page
- 1
- …
- 230
- 231
- 232
- 233
- 234
- …
- 343
- Next Page »